INTS Stock Overview
A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Intensity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.05 |
| 52 Week High | US$11.44 |
| 52 Week Low | US$2.01 |
| Beta | 0 |
| 1 Month Change | 28.66% |
| 3 Month Change | 50.30% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.27% |
Recent News & Updates
Shareholder Returns
| INTS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | -1.7% | -0.3% |
| 1Y | n/a | 7.1% | 25.4% |
Return vs Industry: Insufficient data to determine how INTS performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how INTS performed against the US Market.
Price Volatility
| INTS volatility | |
|---|---|
| INTS Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: INTS's share price has been volatile over the past 3 months.
Volatility Over Time: INTS's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 6 | Lew Bender | www.intensitytherapeutics.com |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. Fundamentals Summary
| INTS fundamental statistics | |
|---|---|
| Market cap | US$69.23m |
| Earnings (TTM) | -US$15.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.6x
P/E RatioIs INTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INTS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.13m |
| Earnings | -US$15.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INTS perform over the long term?
See historical performance and comparison